Reinoud Gosens (Groningen, Netherlands), András Bikov (Budapest, Hungary), Mario Cazzola (Rome, Italy), Pankaj Bhavsar (London, United Kingdom)
Effect of 8 and 12 weeks’ once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with COPD
Thierry Troosters (Glasgow, United Kingdom), Thierry Troosters, Jean Bourbeau, François Maltais, Nancy Leidy, Damijan Erzen, Dorothy De Sousa, Lawrence Korducki, Kim L. Lavoie, Wim Janssens, Alan Hamilton
|   |
Combined tiotropium + olodaterol influences physical functioning in COPD: Results of an open-label observational study
Sauer Ruediger (Ulm, Germany), Sauer Ruediger, Michaela Haensel, Roland Buhl, Roman A. Rubin, Marcel Frey, Andrea Marseille, Thomas Glaab
| |
Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use
Eric Derom (Ghent, Belgium), Eric Derom, Kai-Michael Beeh, José Echave-Sustaeta, Lars Grönke, Dongmei Zhai, Leif Bjermer
| |
Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema
Roland Buhl (Mainz, Germany), Roland Buhl, Eric Derom, Leif Bjermer, Lars Grönke, Florian Voß, Matjaz Flezar
| |
Prevention of deteriorations in COPD on stepping up from tiotropium to umeclidinium/vilanterol
Ian Naya (Uxbridge , United Kingdom), Ian Naya, Lee Tombs, Mitra Vahdati-Bolouri, Chris Kalberg
| |
Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis
Afisi Ismaila (Research Triangle Park , United States of America), Eline Huisman, Katya Sion, Yogesh Punekar, Andreas Karabis, Ian Naya, Afisi Ismaila
| |
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study
Kenneth R. Chapman (Toronto, Canada), Kenneth R. Chapman, Nicolas Roche, Tim Ayers, Angel FowlerTaylor, Chau Thach, Norbert Ahlers, Robert Fogel, Francesco Patalano, Donald Banerji
| |
Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis
Antonio R. Anzueto (San Antonio, United States of America), Antonio R. Anzueto, Konstantinos Kostikas, Karen Mezzi, Sebastian Fucile, Giovanni Bader, Steven Shen, Donald Banerji, Robert Fogel
| |
Effect of indacaterol/glycopyrronium versus salmeterol/fluticasone on hypothalamic pituitary-adrenal axis function in moderate-to-very severe COPD patients: Results from the FLAME study
Petter Olsson (Alvsjo, Sweden), Petter Olsson, Claus Vogelmeier, Kenneth Chapman, Angel FowlerTaylor, Tim Ayers, Chau Thach, Robert Fogel, Francesco Patalano, Donald Banerji
| |
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Paul Michael Larbig (Pfeffingen, Switzerland), Paul Michael Larbig, Claus Vogelmeier, Nicolas Roche, Tim Ayers, Angel FowlerTaylor, Chau Thach, Anupama Shrinivasan, Robert Fogel, Francesco Patalano, Donald Banerji
| |
Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program
Ioanna Tsiligianni (Heraklion, Crete, Greece), Ioanna Tsiligianni, Karen Mezzi, Sebastian Fucile, Konstantinos Kostikas, Steven Shen, Donald Banerji, Robert Fogel
| |
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
Francesco Patalano (Basel, Switzerland), Francesco Patalano, Jadwiga A. Wedzicha, Jørgen Vestbo, Angel FowlerTaylor, Tim Ayers, Chau Thach, Neha Ruparelia, Robert Fogel, Donald Banerji
| |
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies
Antonio R. Anzueto (San Antonio, United States of America), Antonio R. Anzueto, Konstantinos Kostikas, Karen Mezzi, Sebastian Fucile, Giovanni Bader, Steven Shen, Donald Banerji, Robert Fogel
| |
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study
Wisia Wedzicha (London, United Kingdom), Jadwiga Wedzicha, Claus F. Vogelmeier, Tim Ayers, Angel FowlerTaylor, Chau Thach, Petter Olsson, Robert Fogel, Francesco Patalano, Donald Banerji
| |
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
Robert Fogel (East Hanover, United States of America), Robert Fogel, Kenneth R. Chapman, Claus F. Vogelmeier, Angel FowlerTaylor, Tim Ayers, Chau Thach, Sarah Whelan, Karyn Clerkin, Francesco Patalano, Donald Banerji
| |
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Wisia Wedzicha (London, United Kingdom), Jadwiga Wedzicha, Kenneth Chapman, Angel FowlerTaylor, Tim Ayers, Chau Thach, Petter Olsson, Robert Fogel, Francesco Patalano, Donald Banerji
| |
Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts)
Fernando J. Martinez (New York, United States of America), Fernando J. Martinez, Leonardo M. Fabbri, Gary T. Ferguson, Shahid Siddiqui, Chad Orevillo, Patrick Darken, Colin Reisner
| |
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
Samy Suissa (Montreal, Canada), Samy Suissa, Sophie Dell’Aniello, Pierre Ernst
| |
Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts)
Colin Reisner (Morristown, United States of America), Colin Reisner, Gregory Gottschlich, Faisal Fakih, Andras Koser, James Krainson, Luis Delacruz, Samir Arora, Gregory Feldman, Krishna Pudi, Shahid Siddiqui, Chad Orevillo, Andrea Maes
| |
LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients
Géraldine Cohuet (Courbevoie, France), Dave Singh, Alberto Papi, Massimo Corradi, Isabella Montagna, Catherine Francisco, Géraldine Cohuet, Stefano Vezzoli, Annamaria Muraro, Stefano Petruzzelli, Mario Scuri, Jorgen Vestbo
| |